^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FGFR3 overexpression

i
Other names: FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3
Entrez ID:
1year
A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
P2, N=202, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 overexpression • FGF3 overexpression
|
ABSK043 • ABSK061
1year
A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
P2, N=202, Not yet recruiting, Abbisko Therapeutics Co, Ltd
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 overexpression • FGF3 overexpression
|
ABSK043 • ABSK061
over1year
Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression. (PubMed, Exp Mol Med)
Furthermore, we found similarities between CN and radial glial cells based on analyses of gene markers and CN tumor cells and postulate that CN tumorigenesis is due to dysregulation of radial glial cell differentiation into neurons. Our data demonstrate the potential role of FGFR3 as one of the leading drivers of tumorigenesis in CN.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 overexpression • FGF3 overexpression
over1year
Regulatory mechanism of the Glabrene against non-small cell lung cancer by suppressing FGFR3. (PubMed, Environ Toxicol)
Glabrene has the potential as a therapeutic agent for NSCLC by reducing cancer invasion and migration through the inhibition of ERK1/2 phosphorylation and suppression of epithelial-mesenchymal transition (EMT).
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • CDH1 (Cadherin 1) • IGF1 (Insulin-like growth factor 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9) • MMP1 (Matrix metallopeptidase 1)
|
FGFR3 overexpression • CDH1 expression • FGFR3 expression • VIM expression • FGF3 overexpression
over1year
RT-PCR assay to detect FGFR3::TACC3 fusions in formalin-fixed, paraffin-embedded glioblastoma samples. (PubMed, Neurooncol Pract)
RT-PCR for FGFR3::TACC3 fusions can successfully be performed on FFPE material, with a specificity of 100% and (due to limited primer sets) a sensitivity of 83.3%. This assay allows for the identification of potential targeted treatment options when only formalin-fixed tissue is available.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3 overexpression • FGFR3 fusion • IDH wild-type • FGFR3 expression • FGF3 overexpression
almost2years
Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients. (PubMed, Pediatr Blood Cancer)
While both EPN patients did not respond to erdafitinib treatment, the FGFR1-ITD-harbouring tumour showed a significant decrease in tumour volume and contrast enhancement throughout treatment. The tumour remained stable 6 months after treatment discontinuation.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR1 overexpression • FGFR3 overexpression • FGF3 overexpression
|
Balversa (erdafitinib)
almost2years
Comparison of tissue based FGFR mutation detection by Therascreen FGFR with UroTyper FGFR and ADC test and relevance for potential co-targeting with TROP2 and NECTIN4: Preview of Bladder BRIDGister. (ASCO-GU 2024)
Background: In view of the efficacy of FGFR targeting in early and advanced bladder cancer, as has been shown for erdafitinib in the THOR and NORSE trial, molecular testing of FGFR mutations and fusions will soon become clinical routine worldwide... PCR-based FGFR assessment by Therascreen and UroTyper is highly concordant and enables fast, local FGFR assessment within few hours. FGFR3 mutations are associated with increased TROP2 & NECTIN4 expression indicating potential synergistic options which warrants further exploration as part of molecularly stratified clinical trials.
FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
FGFR3 mutation • FGFR mutation • FGFR fusion • FGFR3 S249C • FGFR3 overexpression • FGFR3 Y373C • NECTIN4 expression • FGFR3 G370C • FGFR3 R248C • FGF3 overexpression
|
therascreen® FGFR RGQ RT-PCR Kit • Uromonitor®
|
Balversa (erdafitinib)
2years
FGFR3 and FGFR4 overexpression in juvenile nasopharyngeal angiofibroma: impact of smoking history and implications for personalized management. (PubMed, J Appl Genet)
Furthermore, medical reports indicated higher rates of recurrence and bleeding intensity among smokers. These findings emphasize the potential role of FGFR3 as a key molecular factor in JNA, particularly in the context of smoking.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR3 overexpression • FGFR overexpression • FGFR4 overexpression • FGFR3 expression • FGF3 overexpression
2years
The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder. (PubMed, Asian Pac J Cancer Prev)
The study findings indicate that the intensity and percentage of cell staining for P53 and CK20 in the UCC of the bladder can aid in differentiating the grading patterns. The tendency of tumor relapse can be predicted by demonstrating heterogeneous and non-papillary patterns.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • KRT20 (Keratin 20)
|
FGFR3 overexpression • TP53 expression • FGF3 overexpression • FGFR3 positive
2years
Crocin Combined With Cisplatin Regulates Proliferation, Apoptosis And Emt Of Gastric Cancer Cells Via The Fgfr3/Mapk/Erk Pathway In Vitro And In Vivo. (PubMed, Curr Cancer Drug Targets)
Our results showed that up-regulation of FGFR3 reversed the inhibitory effect of crocin+DDP on the MAPK/ERK signaling pathway. Still, this effect could be counteracted by PD184352, which simultaneously regulated the proliferation, apoptosis, and EMT of AGS cells. In conclusion, crocin, combined with DDP, inhibits proliferation, apoptosis, and EMT of GC through the FRFR3/MAPK/ERK pathway.
Preclinical • Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 overexpression • FGFR3 expression • FGF3 overexpression
|
cisplatin • CI-1040
over2years
ASSESSMENT OF CONVENTIONAL TRANSLOCATIONS AND IG REARRANGEMENTS IN THE DIAGNOSIS OF MULTIPLE MYELOMA PATIENTS USING A TARGETED CAPTURE-HYBRIDIZATION RNA SEQUENCING PANEL. (EHA 2023)
In view of the high concordance found between tchRNA-Seq and FISH, our approach could provide additional relevant molecular information and could be useful for the identification of new biomarkers at diagnosis or relapse. The clustering of patients into cytogenetically defined subgroups by studying up- or down-regulated genes could improve the genetic risk stratification. Nevertheless, it is necessary to increase the cohort size to validate these promising results.
Clinical • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CCND1 (Cyclin D1) • SDC1 (Syndecan 1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CCND3 (Cyclin D3) • NT5C (5', 3'-Nucleotidase, Cytosolic) • TENT5C (Terminal Nucleotidyltransferase 5C)
|
KRAS mutation • FGFR3 overexpression • CCND1 expression • FGFR3 expression • FGF3 overexpression
over2years
AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion (AACR 2023)
AMB302/GR1017 showed robust anti-tumor efficacies in F3-T3 fusion and FGFR3 overexpression models derived from GBM and BC in vitro and in vivo. In addition, AMB302/GR1017 was well tolerated with no adverse effects in rodent model. Our data suggest AMB302/GR1017 has a potential therapeutic option as a first-in-class FGFR3 targeting ADC for GBM, BC, and other solid tumors with FGFR3 overexpression or alterations.
Preclinical
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3-TACC3 fusion • FGFR3 overexpression • FGFR3 fusion • FGFR3 amplification • FGF3 overexpression
|
AMB302